AbbVie Inc

$ 79.98 0.64 (0.81%)
Volume: 2,313,370 Avg Vol (1m): 5,902,362
Market Cap $: 117.74 Bil Enterprise Value $: 149.98 Bil
P/E (TTM): 22.25 P/B: 0.00
Earnings Power Value 27.47
Net Current Asset Value -33.81
Tangible Book -30.14
Projected FCF 54.42
Median P/S Value 91.4
Graham Number 0
Peter Lynch Value 72.86
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.20
Equity-to-Asset -0.14
Debt-to-Equity -4.77
Debt-to-EBITDA 4.85
Interest Coverage 4.74
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.03
DISTRESS
GREY
SAFE
Beneish M-Score -3.14
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 23.82%
WACC 7.16%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 19.49
Net Margin % 17.36
ROA % 8.69
ROC (Joel Greenblatt) % 207.75
3-Year Total Revenue Growth Rate 12.70
3-Year Total EBITDA Growth Rate 0.40
3-Year EPS w/o NRI Growth Rate 5.40

» ABBV's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ABBV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 5122
Compare NYSE:MRK XSWX:NOVN XSWX:ROG NYSE:PFE NYSE:BMY XPAR:SAN XTER:BAYN LSE:GSK LSE:AZN NYSE:LLY TSE:4503 TSE:4519 TSE:4578 TSE:4568 HKSE:01093 TSE:4528 TSE:4151 SHSE:600436 MIL:REC SHSE:600867
Traded in other countries ABBV34.Brazil 4AB.Germany 0QCV.UK
Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie Inc is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013.

Ratios

Current vs industry vs history
PE Ratio (TTM) 22.25
Forward PE Ratio 9.17
N/A
PE Ratio without NRI 22.25
Price-to-Owner-Earnings 20.35
PS Ratio 3.76
Price-to-Free-Cash-Flow 9.58
Price-to-Operating-Cash-Flow 9.12
EV-to-EBIT 22.93
EV-to-EBITDA 18.04
EV-to-Revenue 4.59
PEG Ratio 1.51
Current Ratio 0.98
Quick Ratio 0.89
Days Inventory 78.64
Days Sales Outstanding 60.00
Days Payable 73.11

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 5.11
Dividend Payout Ratio 0.98
3-Year Dividend Growth Rate (Per Share) 21.10
Forward Dividend Yield % 5.39
N/A
Yield-on-Cost (5-Year) % 11.20
3-Year Share Buyback Rate 2.20

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.46
Price-to-Median-PS-Value 0.87
Price-to-Peter-Lynch-Fair-Value 1.09
Earnings Yield (Joel Greenblatt) % 4.36
Forward Rate of Return (Yacktman) % 26.00

More Statistics

Revenue (TTM) (Mil) $ 32,753
EPS (TTM) $ 3.58
Beta 0.99
Volatility % 32.04
52-Week Range $ 75.77 - 107.25
Shares Outstanding (Mil) 1,478.16

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y